Full text is available at the source.
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety
Creating and testing new quinoline compounds with 1,2,4-oxadiazole for tuberculosis treatment
AI simplified
Abstract
The compound QD-19 to QD-21 demonstrated a minimum inhibitory concentration (MIC) value of 0.25 µg/ml against Mycobacterium tuberculosis.
- Twenty-one new derivatives of 1,2,4-oxadiazol-3-ylmethyl-piperazin-1-yl-quinoline were synthesized and evaluated for their effectiveness against tuberculosis.
- QD-18 showed a promising MIC value of 0.5 µg/ml, indicating strong antitubercular potential.
- Compounds QD-19, QD-20, and QD-21 exhibited an even lower MIC value of 0.25 µg/ml.
- These compounds were assessed for metabolic stability, cytotoxicity, and pharmacokinetics, confirming their safety and effectiveness.
- The results suggest that QD-18, QD-19, QD-20, and QD-21 could serve as lead candidates for new antitubercular drugs.
AI simplified